Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by “mutating” the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.
Peter Schiff Gets Roasted For Mocking Ukraine President Zelensky’s Clothing
If the Joan Rivers series “Fashion Police” is ever rebooted, Peter Schiff might be in the running for the hosting gig.
